{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-113898","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-10-06T12:07:09+00:00","discovered_at":"2026-10-06T12:10:00.363138+00:00","generated_at":"2026-10-12T16:33:17.756173+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ArriVent's Phase 3 FURVENT trial misses primary PFS endpoint; firmonertinib 240mg PFS 11.0 vs 9.5 months (p=0.0654)","bullets":["FURVENT Phase 3 trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed primary endpoint of PFS by BICR: 240mg 11.0 months vs control 9.5 months, p=0.0654, HR 0.75.","160mg arm median PFS 8.4 months, HR 0.91; investigator-assessed PFS 11.1 vs 8.3 vs 7.1 months, HR 0.61 (0.46, 0.81) for 240mg vs control.","Confirmed ORR by BICR: 60% for firmonertinib 240mg, 35% for 160mg, 33% for control; investigator-assessed ORR 61%, 41%, 28%.","Safety consistent with prior studies, no new signals; Grade >=3 TEAEs 52% (240mg), 53% (160mg), 55% (control); Grade >=3 TRAEs 26%, 22%, 40%.","CEO Bing Yao called the results 'disappointing'; ArriVent says it is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-113898","json":"https://secwatch.observer/filing/0001104659-26-113898.json","markdown":"https://secwatch.observer/filing/0001104659-26-113898.md","text":"https://secwatch.observer/filing/0001104659-26-113898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/0001104659-26-113898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/tm2627092d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:33:17.756173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}